
Takeda San Diego re-acquires DPP4 rights
Executive Summary
Takeda San Diego (formerly Syrrx, before its acquisition by Takeda Pharmaceutical in February 2005) has re-acquired worldwide development and marketing rights to the dipeptidyl peptidase IV (DPP4) inhibitors that it formerly shared with PPD under a 2003 agreement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice